4 research outputs found
Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells
The use of c-abl-specific inhibitors such as Imatinib (IM)
or Dasatinib has revolutionized the treatment of chronic
myeloid leukemia (CML). However, a significant percentage
of patients become resistant to IM. In this report, we
have analyzed the possibility of using the proteasome as a
molecular target in CML. Our results show that cells that
express Bcr-Abl1 are more sensitive to the inhibition of
the proteasome with Bortezomib (Btz) than control cells.
This treatment reduces the proliferation of Bcr-Abl1-
expressing cells, by inactivating NF-jB2 and decreasing
the phosphorylation of Rb, eventually leading to an
increase in caspase-dependent apoptosis. Furthermore,
we show that Btz also induces cell-cycle arrest and
apoptosis in cells expressing Bcr-Abl1 mutants that are
resistant to IM. These results unravel a new molecular
target of Btz, that is the Rb pathway, and open new
possibilities in the treatment of CML especially for
patients that become resistant to IM because of the
presence of the T315I mutation
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells
Chronic myelogenous leukemia (CML) is characterized by the expression of the BCR-ABL tyrosine kinase, which results in increased cell proliferation and inhibition of apoptosis. In this study, we show in both BCR-ABL cells (Mo7e-p210 and BaF/3-p210) and primary CML CD34+ cells that STI571 inhibition of BCR-ABL tyrosine kinase activity results in a G(1) cell cycle arrest mediated by the PI3K pathway. This arrest is associated with a nuclear accumulation of p27(Kip1) and down-regulation of cyclins D and E. As a result, there is a reduction of the cyclin E/Cdk2 kinase activity and of the retinoblastoma protein phosphorylation. By quantitative reverse transcription-PCR we show that BCR-ABL/PI3K regulates the expression of p27(Kip1) at the level of transcription. We further show that BCR-ABL also regulates p27(Kip1) protein levels by increasing its degradation by the proteasome. This degradation depends on the ubiquitinylation of p27(Kip1) by Skp2-containing SFC complexes: silencing the expression of Skp2 with a small interfering RNA results in the accumulation of p27(Kip1). We also demonstrate that BCR-ABL cells show transcriptional up-regulation of Skp2. Finally, expression of a p27(Kip1) mutant unable of being recognized by Skp2 results in inhibition of proliferation of BCR-ABL cells, indicating that the degradation of p27(Kip1) contributes to the pathogenesis of CML. In conclusion, these results suggest that BCR-ABL regulates cell cycle in CML cells at least in part by inducing proteasome-mediated degradation of the cell cycle inhibitor p27(Kip1) and provide a rationale for the use of inhibitors of the proteasome in patients with BCR-ABL leukemias
Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells
The use of c-abl-specific inhibitors such as Imatinib (IM)
or Dasatinib has revolutionized the treatment of chronic
myeloid leukemia (CML). However, a significant percentage
of patients become resistant to IM. In this report, we
have analyzed the possibility of using the proteasome as a
molecular target in CML. Our results show that cells that
express Bcr-Abl1 are more sensitive to the inhibition of
the proteasome with Bortezomib (Btz) than control cells.
This treatment reduces the proliferation of Bcr-Abl1-
expressing cells, by inactivating NF-jB2 and decreasing
the phosphorylation of Rb, eventually leading to an
increase in caspase-dependent apoptosis. Furthermore,
we show that Btz also induces cell-cycle arrest and
apoptosis in cells expressing Bcr-Abl1 mutants that are
resistant to IM. These results unravel a new molecular
target of Btz, that is the Rb pathway, and open new
possibilities in the treatment of CML especially for
patients that become resistant to IM because of the
presence of the T315I mutation
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells
Chronic myelogenous leukemia (CML) is characterized by the expression of the BCR-ABL tyrosine kinase, which results in increased cell proliferation and inhibition of apoptosis. In this study, we show in both BCR-ABL cells (Mo7e-p210 and BaF/3-p210) and primary CML CD34+ cells that STI571 inhibition of BCR-ABL tyrosine kinase activity results in a G(1) cell cycle arrest mediated by the PI3K pathway. This arrest is associated with a nuclear accumulation of p27(Kip1) and down-regulation of cyclins D and E. As a result, there is a reduction of the cyclin E/Cdk2 kinase activity and of the retinoblastoma protein phosphorylation. By quantitative reverse transcription-PCR we show that BCR-ABL/PI3K regulates the expression of p27(Kip1) at the level of transcription. We further show that BCR-ABL also regulates p27(Kip1) protein levels by increasing its degradation by the proteasome. This degradation depends on the ubiquitinylation of p27(Kip1) by Skp2-containing SFC complexes: silencing the expression of Skp2 with a small interfering RNA results in the accumulation of p27(Kip1). We also demonstrate that BCR-ABL cells show transcriptional up-regulation of Skp2. Finally, expression of a p27(Kip1) mutant unable of being recognized by Skp2 results in inhibition of proliferation of BCR-ABL cells, indicating that the degradation of p27(Kip1) contributes to the pathogenesis of CML. In conclusion, these results suggest that BCR-ABL regulates cell cycle in CML cells at least in part by inducing proteasome-mediated degradation of the cell cycle inhibitor p27(Kip1) and provide a rationale for the use of inhibitors of the proteasome in patients with BCR-ABL leukemias